Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ATF4 | P18848 | 8/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20999062 | 0.96 | ALDH1A1 (0.50) | ALDH1A1ATF4GRIN1GRIN2B | |
| SCHEMBL20999710 | 0.94 | MEN1 (0.47) | ALDH1A1ATF4LMNATP53SMN1; SMN2 | |
| SCHEMBL20999087 | 0.93 | ALDH1A1 (0.46) | ALDH1A1ATF4SMN1; SMN2GAA | |
| SCHEMBL20999659 | 0.92 | ALDH1A1 (0.47) | ALDH1A1ATF4GRIN1GRIN2B | |
| SCHEMBL20999111 | 0.92 | HDAC1 (0.53) | ALDH1A1ATF4LMNAGRIN1GRIN2B | |
| SCHEMBL20999593 | 0.91 | ALDH1A1 (0.46) | ALDH1A1ATF4GRIN1GRIN2B | |
| SCHEMBL22669317 | 0.91 | ALDH1A1 (0.43) | ALDH1A1ATF4SMN1; SMN2 | |
| SCHEMBL20999096 | 0.91 | ALDH1A1 (0.44) | ALDH1A1ATF4TP53SMN1; SMN2 | |
| SCHEMBL20999316 | 0.91 | ALDH1A1 (0.44) | ALDH1A1ATF4GRIN1GRIN2B | |
| SCHEMBL22668994 | 0.90 | ATF4 (0.43) | ALDH1A1ATF4GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361941-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361941-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ALDH1A1 3433/4885ATF4 1/4885LMNA 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.